Jagsonpal amongst India's top fifty pharma companies
By Our Corporate Bureau | 16 Jun 2004
New Delhi: Jagsonpal Pharmaceuticals, engaged in the manufacturing and marketing of bulk drugs, has been included amongst the top 50 pharma companies in India for March 2004 at rank 42 according to an independent pharmaceutical audit agency - IMS. The company''s main focus is on the niche segments of pharmaceutical formulations and bulk drugs.
Jagsonpal is also present in the ''branded segment'' of the formulations'' market. The company is focused on a select number of therapeutic groups, namely anti-arthritics, analgesics, anti-inflammatories, anti-spasmodics, anabolic steroids, progesterones, anesthetics and anti-fungals.
The company has a modern WHO and GMP-certified manufacturing facility for the production of various dosage forms and bulk drugs/intermediates. All major products of Jagsonpal have showed an upward sales trend with Lycored - it''s antioxidant brand - registering a business of over Rs 12 crores in the first year of it''s operations. It has consolidated its position within other therapeutic segments as well with brands such as Maintane, Metadec, Metabol, Doxypal-DR, Parvon range, Indocap SR (all salts), Indocap SR (Indomethacin) consistently scaling up the sales chart. Jagsonpal''a bulk drugs product profile includes dextropropoxyphene HCl, dextropropoxyphene napsylate, tolnaftate and thiopental sodium.
The financial performance of the company in the last quarter was at an all-time high on all parameters. Sales went up by a huge 75 percent for the quarter ended March 2004 at Rs 4113.14 lakhs as against Rs. 2351.15 lakhs in the corresponding quarter last year.
